Introduction
A key challenge in the development of immunotherapeutic modalities for malignant glioma has been overcoming local immunoresistance and systemic immunosuppression [1] . For example, B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), induces apoptosis of activated T-cells and hinders tumor-specific killing by cytotoxic T-cells when expressed on the cell surface of glioma [2] . As normal human cells contain B7-H1 transcript, they usually express little or no B7-H1 protein [2] [3] [4] . In malignant glioma, B7-H1 protein is expressed at high levels [5] [6] [7] [8] [9] [10] , with a correlation between level of B7-H1 protein expression and tumor grade [10] . Deficiency of the tumor suppressor gene, phosphatase and tensin homolog (PTEN) function results in increased expression of the B7-H1 protein through a well-defined posttranscriptional mechanism that is dependent on the PI3-kinase (PI3K) pathway and S6 kinase activation [11] .
Gamma interferon (IFN-g) is a powerful immunomodulatory cytokine secreted by activated T-cells. IFN-g increases immunogenicity of target cells, including glioma cells, by upregulation of major histocompatibility complex class I and class II expression on gliomas [12, 13] . Paradoxically, a potential pathway to immunoresistance conferred by IFN-g in context of human glioma has been demonstrated by Wilmotte et al. [10] , who noted that the expression of B7-H1 protein is partly IFN-g dependent. In this study, we hypothesized that an increase in B7-H1 transcript after IFN-g treatment would result in superinduction of B7-H1 protein in patients with PTEN loss, mediated in part by posttranscriptional regulatory mechanisms, conferring an extremely immunoresistant phenotype.
Materials and methods

Immunohistochemistry
Immunohistochemistry was performed at the University of California at San Francisco (UCSF), Department of Pathology. Hematoxylin and Eosin and PTEN stains were performed on Paraffin blocks of tumor samples processed on BenchMark XT (Ventana Medical Systems, Tucson, Arizona, USA). Rabbit anti-human PTEN antibody (Cell Signaling, Danvers, Massachusetts, USA) was used at 1 : 100 dilution. The average percentage of tumors cells with positivity to PTEN stain of three high power fields was measured to categorize the tumor into the four widely accepted PTEN score categories: 0-25, 25-50, 50-75, and 75-100% [14] .
Normal human astrocyte cell line preparation
Retroviral transfection of normal human astrocyte (NHAs) (Clonetics, Walkersville, Maryland, USA) produced cells with genetic alterations functionally equivalent to those in human malignant gliomas. Immortalized hTERT/ E6/E7 cells were produced by introduction of pWZLblast-hTERT and pLXSP-puro-E6/E7. Ras + cells were generated by independent retroviral introduction of pLXSN-neo-H-RasV12. Akt + cells and Ras + /Akt + cells were created by independent retroviral infections of Ras + cells with pWZL-hygro-myrAktdelta4-129.
Glioma cell cultures
Well-characterized glioma cell lines, U87 and SF767, were obtained from the UCSF Brain Tumor Research Center, and cultured in Dulbecco's Modified Eagle Medium (DME H-21; Invitrogen, Carlsbad, California, USA) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
Primary human glioblastoma cell lines were derived from tumor samples that were resected from patients treated at UCSF Medical Center, with the approval of the UCSF Medical Center Institutional Review Board and Committee on Human Research. Glioma cells were isolated by mechanical and enzymatic dissociation, followed by density separation by Percoll (Sigma-Aldrich, St. Louis, Missouri, USA) gradient. Twenty-six different glioblastoma multiforme lines were established and cultured in RPMI-1640 (Invitrogen) 25 M Hepes and 2.0 g/l NaH-CO 3 , with 25% FBS, 1% penicillin-streptomycin, 1 mM sodium pyruvate, 10 mM nonessential amino acids.
Isolation of peripheral blood lymphocytes and T cells
Peripheral blood lymphocytes (PBLs) were isolated from whole blood of patients collected at the time of surgery by density gradient using Ficoll-Paque (GE HealthCare, Piscataway, New Jersey, USA). From six patients, T cells were isolated from the population of PBLs using the CD3 Human T-cell Enrichment Kit (Stem Cell Technologies, Vancouver, British Columbia, Canada). Tcells were cultured in the complete T-cell medium containing RPMI-1640 25 M Hepes and 2.0 g/l NaHCO 3 , with 10% FBS, 1% penicillin-streptomycin, 1 mM sodium pyruvate, 10 mM nonessential amino acids, and expanded by stimulation with anti-CD3 (2 mg/ml) and anti-CD28 (5 mg/ml) antibodies (eBioscience, San Diego, California, USA).
Treatment with gamma interferon and inhibitors of the PI3-kinase pathway
NHAs and tumor cells (1 Â 10 5 cells/ml) were treated with recombinant human IFN-g (R&D Systems, Minneapolis, Minnesota, USA) at 100 units/ml for 18 h, and/or with one of the following four inhibitors of the PI3K pathway for 48 h: AKT inhibitor III (AKT III) at 50 mM (Calbiochem, San Diego, California, USA), LY 294002 (LY294) at 100 mM (Calbiochem), Rapamycin (Rapa) at 100 mM (Calbiochem), and Honokiol (HNK) at 20 mM (Dr Jack Arbiser, Emory University) [15] . Different steps of the PI3K pathway were targeted: PI3K by LY294, Akt by AKT III and HNK, and mTOR by Rapa.
Cytotoxic assays
Tumor cells treated with or without IFN-g and/or PI3K pathway inhibitors were plated at 1 Â 10 5 cells/ml and allowed to adhere; next, stimulated autologous PBLs or T cells were added to the same patients' tumor cells. Cells were cocultured for 18 h, and prepared for flow cytometric analysis. As positive control for apoptosis, cells treated with 1 mM staurosporine, a nonspecific kinase inhibitor, (Sigma-Aldrich) were used. On flow cytometric analysis, cell viability was monitored by gating on cell size and granularity and counting of cells that were CD45 positive, but Annexin V negative.
Quantitative PCR mRNA of B7-H1 was obtained from tumor cells using the RNeasy Mini Kit (Qiagen, Valencia, California, USA) and cDNA was generated using the Superscript III Kit (Invitrogen). Transcript levels were detected using the SYBR Green (Applied Biosystems, Foster City, California, USA) and the CFX96 Real-Time System (Bio-Rad Laboratories, Hercules, California, USA). Values of transcript levels were standardized using hypoxanthine phosphoribosyltransferase (HPRT), which has been shown not to be transcriptionally regulated by IFN-g [16] . Sequences of primers used were: B7-H1 (5 0 -GCTGTT-GAAGGA CCAGCT-CT/TGCTTG-TCCAGA-TGACTT-CG-3 0 ) and HPRT (5 0 -GACCAG-TCAACA-GGGGAC-AT/CCTGACC AAGGA-AAGCAA-AG-3 0 ).
Flow cytometry
Tumor samples were stained with FITC-conjugated HLA-ABC (BD Biosciences, Franklin Lakes, New Jersey, USA) and PE B7-H1 (eBioscience). Samples from coculture were stained with APC-conjugated CD45 (eBioscience) and PE Annexin V (BD Biosciences). Flow cytometry data were gathered on FACSCaliber Flow Cytometer using the CellQuest Pro software (BD Biosciences), and analyzed with the FlowJo software (Treestar, Ashland, Oregon, USA).
Statistical analysis
For two sample comparisons, the two-tailed Student's t-test was used with statistical significance at the P value of less than 0.05. For multiple comparisons, analysis of variance was used. Significance levels for multiple comparison tests were adjusted using the Bonferroni correction. Data for figures were collected from independent experiments performed in triplicate. Representative experimental data are shown for B7-H1 quantitative PCR, B7-H1 flow cytometry, and T-cell apoptosis experiments. Error bars represent standard deviation, unless otherwise stated.
Results
Previous reports have established that immortalized NHAs do not differ in their expression levels of B7-H1 protein from their normal counterparts [11] . Here, NHAs transfected with E6/E7 did not show a significant increase in level of B7-H1 protein expression when treated with IFN-g, whereas both Ras + NHAs and Akt + NHAs showed a significant increase in B7-H1 protein expression levels with IFN-g treatment (Fig. 1 ).
Exposure to IFN-g resulted in a dramatic increase in B7-H1 protein levels in Ras + /Akt + NHAs (Fig. 1) .
In vivo, glioblastoma multiforme cells show a range of functional PTEN expression ( Fig. 2b and d) , and loss of PTEN is correlated with activation of the PI3K pathway and increased B7-H1 expression [11] . Based on immunohistochemical findings of PTEN levels, established glioma cell lines were categorized as PTEN deficient (PTEN -), if positive staining was found in 0-25% of cells (two of six cell lines) or in 25-50% of cells (one of six). Tumors were considered PTEN intact (PTEN + ), if positive staining was found in 50-75% of cells (one of six) or in 75-100% of cells (two of six).
Transcript levels of B7-H1 were not significantly different in PTEN -tumors compared with PTEN + tumors at baseline (Fig. 3a) . In contrast, expression levels of B7-H1 protein were significantly higher in PTEN -tumors compared with PTEN + tumors at baseline (Fig. 3b ). Treatment with IFN-g resulted in increased B7-H1 transcript and protein expression in both PTEN -and PTEN + cell lines ( Fig. 3a and b ). In addition, IFN-g induced a significantly larger degree of increase in levels of B7-H1 protein and transcript in PTEN -tumor cells than in PTEN + tumors ( Fig. 3a and b) .
To investigate the functional consequences of the observed superinduction of B7-H1 in PTEN -tumors Proportions of viable cells were determined by those with normal size and granularity, negativity for Annexin V stain, and positivity for CD3 ± CD45. As illustrated in Fig. 3c , coculture of autologous lymphocytes with PTEN -tumor cells resulted in a significantly higher degree of lymphocyte apoptosis than coculture of lymphocytes with autologous PTEN + tumor cells (mean % apoptosis: 45 and 12%, respectively; P < 0.001). Coculture with autologous PTEN -tumor cells treated with IFN-g showed a significantly increased degree of lymphocyte apoptosis (mean % apoptosis from 45 to 72%; P < 0.001), along with decreased subsets of viable lymphocytes. For samples from patients with PTEN + tumor, coculture experiments after treatment of tumors with IFN-g did not show a significantly higher degree of lymphocyte apoptosis.
After coculture with autologous tumor cells, T cells of patients with PTEN -tumors had equivalent levels of tumor-induced apoptosis as T cells derived from patients with PTEN + tumors (Fig. 3d ). Compared with coculture with tumors without treatment of IFN-g, T cells after coculture with autologous PTEN -tumor cells treated with IFN-g resulted in a significantly increased level of apoptosis (23-64%; P < 0.001). After IFN-g treatment, there was also a decrease in proportion of viable T cells (data not shown). This increase in apoptosis was not observed for coculture experiments utilizing samples from PTEN + glioma patients.
To determine whether the effects of IFN-g seen above on levels of B7-H1 protein and T-cell apoptosis are mediated by activation of the PI3K pathway, B7-H1 protein measurements using flow cytometry and T-cell killing assays were repeated with tumors after treatment with inhibitors of the PI3K pathway, AKT III, LY294, Rapa, and HNK. For PTEN -samples, inhibition of the PI3K pathway decreased the B7-H1 levels of IFN-g-treated tumor cells to levels before treatment with IFN-g (Fig. 4a ). The percentage of T cells undergoing apoptosis after coculture with autologous PTEN -glioma cells treated with IFN-g was greatly reduced by treatment of any of the four PI3K inhibitors before coculture (Fig. 4c ). 
Discussion
In this report, we studied the induction of B7-H1 protein expression by IFN-g in the context of PTEN loss and PI3K pathway activation. In normal astrocytes with activated downstream targets of the PI3K pathway and tumor cell lines deficient of PTEN, treatment with IFN-g resulted in a superinduction of B7-H1 protein.
IFN-g also induces a strong immunoresistant phenotype in glioma cells, as seen in lymphocyte and T-cell apoptosis assays and autologous coculture experiments. In PTEN -gliomas, which have a greater degree of immune evasion in part because of B7-H1, this immunoresistant phenotype is more pronounced through the IFN-g-mediated B7-H1 superinduction and the associated increase in T-cell apoptosis. Considering that the two observed effects are both abrogated by PI3K pathway inhibition, our observations identify the activated oncogenic PI3K pathway as a potential therapeutic target for adjuvants to immunotherapies.
Conclusion
Here, we demonstrate that the immunoresistant protein B7-H1 is dramatically upregulated after IFN-g treatment of PTEN -glioma cells, with associated increases in lymphocyte and T-cell apoptosis in coculture. Our report suggests that this IFN-g-mediated superinduction of B7-H1 protein contributes to the immune-evasive phenotype of human glioma, identifying a subset of glioma patients who are particularly resistant to T-cell-based immunotherapeutic modalities.
